

Emerging Role of Antibody-Drug Conjugates in the Management of Non-Small Cell Lung Cancer (Faculty Presentations)

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. Based on interim results of the Phase II DESTINY-Lung02 trial, trastuzumab deruxtecan received accelerated approval for which dose schedule?
 - a. 1.4 mg/kg every 3 weeks
 - b. 3.4 mg/kg every 3 weeks
 - c. 5.4 mg/kg every 3 weeks
 - d. 6.4 mg/kg every 3 weeks

2. What was observed in a Phase I, dose-escalation/expansion study of patritumab deruxtecan for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with an EGFR mutation who had undergone prior EGFR tyrosine kinase inhibitor (TKI) therapy?
 - a. Responses were only observed in patients with EGFR-activating mutations
 - b. Responses were only observed in patients with EGFR T790M mutations
 - c. Responses were observed in patients with a range of EGFR and non-EGFR mutations

3. Which of the following drug types best describes the mechanism of action of datopotamab deruxtecan?
 - a. Anti-TROP2 antibody-drug conjugate
 - b. Anti-HER2 antibody-drug conjugate
 - c. Anti-CEACAM5 antibody-drug conjugate
 - d. Anti-HER3 antibody-drug conjugate

4. Emerging results from the Phase Ib TROPION-Lung02 trial evaluating datopotamab deruxtecan/pembrolizumab doublet therapy or the triplet of datopotamab deruxtecan/pembrolizumab/platinum chemotherapy in patients with metastatic NSCLC demonstrated which of the following outcomes?
 - a. Encouraging overall response rate (ORR) with the doublet combination only as first-line therapy
 - b. Encouraging ORR with the triplet therapy combination only as first-line therapy
 - c. Encouraging ORRs with the doublet and triplet therapy combinations as first-line therapy

5. Which of the following is targeted by the antibody-drug conjugate tusamitamab ravtansine?
 - a. HER2
 - b. HER3
 - c. TROP2
 - d. CEACAM5
 - e. MET